Comera | Investor Presentation Deck | 22 slides

Comera Life Sciences · 2023-02
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 5 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
0/1 slides
100% 1/1 slides
0/1 slides
100% 1/1 slides
0/1 slides
Proposed Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
0/1 slides
0/1 slides
0/1 slides
100% 1/1 slides
0/1 slides
Methodology 2 slides 100% 2/2 slides 100% 2/2 slides · 13 hits
0/2 slides
0/2 slides
50% 1/2 slides 100% 2/2 slides
0/2 slides
Key Takeaways 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
0/1 slides
0/1 slides
0/1 slides
100% 1/1 slides
0/1 slides

Slide inventory

22
every slide · same image gating as the playbook
01
Slide 1
front_matter
02
summarize
03
Uses a before-after visual metaphor with a clock for IV and a 1-minute timer for SQ.present_solution
04
The slide uses a conceptual graph showing the relationship between concentration, PPI, and viscosity, alongside a molecular diagram showing protein aggregation.frame_problem
Open slide detailBeat · Problem Statement
05
The slide illustrates the mechanism of action for the SQore platform, showing the transition from high-viscosity, high-PPI protein clusters to low-viscosity, lopresent_solution
Open slide detailBeat · Proposed Solution
06
The slide uses a funnel diagram to represent the development process and a circular flow diagram for biophysical studies.present_framework
07
The slide illustrates a computational workflow for drug formulation optimization.present_solution
08
The slide outlines a three-step computational process: identifying interaction sites, screening a library (SQore), and ranking results.present_solution
09
The slide uses visual comparisons of protein structures and corresponding RMSD and Hydrogen Bond plots to demonstrate the utility of MD simulations.analyze_data
Open slide detailBeat · Methodology
10
The slide illustrates a dual-track approach (biophysical studies vs. computational modeling) feeding into an excipient selection matrix.present_framework
Open slide detailBeat · Methodology
11
Shows CD thermal melt data for Nivolumab, Trastuzumab, Pembrolizumab, and Ustekinumab.analyze_data
Open slide detailBeat · Key Takeaways
12
Data shows percentage of monomer remaining for different stabilizer formulations compared to control.analyze_data
13
Data presented as bar charts showing particle counts per ml across different size ranges.analyze_data
14
Shows sensorgrams for different concentrations of stabilizers.analyze_data
15
transition
16
The DLS screen shows hydrodynamic radius (Rh) over time for various buffers; the accelerated stress screen compares 0-week vs 2-week stability across four buffeanalyze_data
17
The slide displays three distinct charts: two BLI sensorgrams (top left and bottom left) and one viscosity vs concentration scatter plot (right).analyze_data
18
The slide demonstrates a progression from initial screening (DLS) to final stability assessment (monomer loss) to justify the selection of specific excipient coanalyze_data
19
Includes a scatter plot, bar chart, line chart, and summary table comparing different stabilizer mixtures.analyze_data
20
Includes a bar chart of DOE samples, a linear regression plot of pH vs monomer, and a heatmap of sugar vs pH.analyze_data
21
summarize
22
closing_ask